Eli Lilly is currently redefining its market position through a series of strategic developments. The pharmaceutical giant finds itself at a pivotal moment, ...

Competition is working, even as the FTC meddles in a takeover fight in a way that helped Pfizer.

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...

A solid clinical win for a promising candidate helped jolt the stock a few months ago. And just last week, the company's ...

Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

There’s a lot of buzz about the popular GLP-1 weight loss drugs after President Donald Trump announced this week a deal with ...

Experts say the deal to lower the cost of the drugs is ambitious, but left some with more questions than answers.

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

Eli Lilly collaborates with the Trump administration to improve access to GLP-1 receptor agonists for millions of Americans, including those on government programs. The agreement allows Medicare ...